Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cashewin is a hydro-alcoholic herbal extract derived from the residues of the cashew apple (Anacardium occidentale L.), a byproduct of the cashew nut industry. Developed and commercialized by Dialpha, this oral supplement is standardized to contain bioactive polyphenols, specifically derivatives of myricetin and quercetin flavonoids, alongside anacardic acid and vitamin C. Preclinical research in diet-induced obesity models has demonstrated that Cashewin can reduce body-weight gain, limit fat storage in adipose and liver tissues, and improve metabolic markers such as hyperglycemia, hyperinsulinemia, and insulin resistance. While its exact molecular targets are still being characterized, it is positioned for weight management and the prevention of metabolic disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cashewin.